Institut Pasteur

National Institute of Health and Medical Research

Institut Pastuer

Felix Romain

Gilles Marchal

Pascale Pescher

Anne Laqueyrerie

Micheline Lagranderie

Bernardo Boris Vargaftig

Marie-Anne Nahori

Jean Lefort

Georges Hekimian

Philippe Peltre

Cynthia Horn

This application relates to compositions comprising components prepared from Gram positive bacteria such as Gram positive facultative intracellular bacteria for treatment of disorders comprising an immune dysregulation in humans and animals.

Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation

Compositions comprising components prepared from Gram positive bacteria such as Gram positive facultative intra-cellular bacteria, for example mycobacteria, including extended freeze-dried killed Gram positive bacteria, their method of preparation and their use in humans and animals, for the prevention and/or the treatment of disorders comprising an immune dysregulation such as cancer, autoimmune diseases, allergy and tuberculosis.

Gram positive bacteria preparations for the treatment of disease comprising an immune dysregulation

The invention concerns immunogenic glycopeptides derived from pathogenic microorganisms, useful for vaccination and diagnosis of infections caused by said pathogenic microorganisms (bacteria or fungi), and methods for selecting them and preparing them. Said glycopeptides are selected in the group consisting of: a1) glycopeptides essentially consisting of a glycosylated T epitope, comprising 14 to 25 amino acids, among which at least a neutral amino acid is bound to a di- or to a trisaccharide (glycoside linkage) and at least 15% among said amino acids are proline, one of the proline being located in position &#x2212;1 to &#x2212;4, relative to the position of said neutral amino acid, which glycopeptides are: exhibited by a class II MHC molecule, specifically identified by T CD+4 lymphocytes induced by immunization with the native glycopeptide from which they are derived, but are not identified by the T CD+4 lymphocytes induced by immunization with a non-glycosylated peptide of same sequence and capable of inducing a proliferation of said T CD+4 lymphocytes by which they are identified and the secretion of cytokines by said lymphocytes and b1) glycopeptides having a sequence of 15 to 39 amino acids including the sequence of the glycopeptide as defined in a1), excluding the glycopeptide of sequence SEQ ID NO:11.

Immunogenic glycopeptides, screening, preparation and uses

The invention concerns immunogenic glycopeptides derived from pathogenic microorganisms, useful for vaccination and diagnosis of infections caused by said pathogenic microorganisms (bacteria or fungi), and methods for selecting them and preparing them. Said glycopeptides are selected in the group consisting of: a1) glycopeptides essentially consisting of a glycosylated T epitope, comprising 14 to 25 amino acids, among which at least a neutral amino acid is bound to a di- or to a trisaccharide (glycoside linkage) and at least 15% among said amino acids are proline, one of the proline being located in position &#x2212;1 to &#x2212;4, relative to the position of said neutral amino acid, which glycopeptides are: exhibited by a class II MHC molecule, specifically identified by T CD+4 lymphocytes induced by immunisation with the native glycopeptide from which they are derived, but are not identified by the T CD+4 lymphocytes induced by immunisation with a non-glycosylated peptide of same sequence and capable of inducing a proliferation of said T CD+4 lymphocytes by which they are identified and the secretion of cytokines by said lymphocytes and b1) glycopeptides having a sequence of 15 to 39 amino acids including the sequence of the glycopeptide as defined in a1), excluding the glycopeptide of sequence SEQ ID NO:11.

protein having a molecular weight of 28 779 Da, and hybrid proteins containing at least portions of its sequence. These proteins may in particular be used in vaccines or for the detection of specific tuberculosis antibodies.

Mycobacterial proteins, microorganisms producing them and their use for vaccines and the detection of tuberculosis

Mycobacterial proteins, microorganisms producing them and their use for vaccines and for the detection of tuberculosis

Mycrobacterial proteins, microorganisms producing same and uses of said proteins in vaccines and for detecting tuberculosis

Antibodies that bind,28 kDa proteins and immune complexes between the antibodies and proteins.

Antibodies Which Bind Mycobacterial Tuberculosis Proteins

Mycobacterium proteins, in particular those of M. bovis, having molecular weights between approximately 44.5 and 47.5 kD. These proteins can have molecular weights of approximately 45 kD or 47 kD and isoelectric pH of approximately 3.7 (45 and 47 kD proteins) and 3.9 (47 kD proteins). These proteins or hybrid proteins containing a part of their sequences can be used as vaccines or as drugs, or for the detection and monitoring of tuberculosis in particular in man and in cattle.

Mycobacterium proteins and applications

Mycobacterium tuberculosis protein having a molecular weight of 20 779 Da, and hybrid proteins containing at least portions of its sequence. These proteins may in particular be used in vaccines or for the detection of specific tuberculosis antibodies.

Mycobacterial proteins, microorganisms producing them and their use for

Mycobacterium tuberculosis protein having a molecular weight of 28 779 Da, and hybrid proteins containing at least portions of its sequence. These proteins may in particular be used in vaccines or for the detection of specific tuberculosis antibodies.

Growing community of inventors

Fontenay Les Briis, France

Felix Romain